You're contacting media contact of this press release

Title: Neuralia TMS Delivers Advanced TMS Therapy for OCD Treatment

Australia, 17th Mar 2026 - Neuralia TMS, a leader in non-invasive neurological treatments, has announced an expansion of its services to include transcranial Direct Current Stimulation (tDCS), an at-home neuromodulation therapy, as well as pharmacogenetic testing to optimise treatment outcomes. Known for its expertise in Transcranial Magnetic Stimulation (TMS) therapy, Neuralia TMS continues to provide evidence-based, drug-free treatments for individuals experiencing conditions such as depression, anxiety, PTSD, obsessive-compulsive disorder (OCD), chronic pain, and Parkinson's disease.Dr Shanek Wick, Medical Director at Neuralia TMS, provided insight into the company’s latest offerings: "The integration of transcranial Direct Current Stimulation (tDCS) into the treatment portfolio reflects a commitment to exploring advanced, personalised approaches to neuromodulation therapy. tDCS provides patients with a flexible, at-home option that complements the clinical applications of TMS therapy, contributing to enhanced mental health and overall wellness."TMS therapy, a proven method for treating conditions like depression, is a cornerstone of Neuralia TMS’s services. The addition of tDCS expands the available treatment options, responding to growing demand for non-invasive and patient-centred therapies. tDCS works by applying a low electrical current to targeted brain areas, helping to modulate brain activity and support mental well-being. Unlike TMS, which is administered in a clinical setting, tDCS offers patients the convenience of managing their treatment from home, thereby broadening the accessibility of these therapies.Pharmacogenetic testing is another important development within Neuralia TMS's comprehensive treatment approach. By analysing patients' genetic profiles,...

This press release is issued by King Newswire